Marwa Zaied, Head of the Department of Medical Oncology at the Birket Elsaba General Hospital, shared a post on LinkedIn:
“ASCO 2026 Takeaway: Could GLP-1 Drugs Reduce Cancer Progression?
One of the most discussed studies at ASCO 2026 wasn’t a new chemotherapy or immunotherapy.
It was about obesity medicine.
In Abstract 3143, researchers from the Cleveland Clinic analyzed more than 12,000 patients with stage I–III obesity-related cancers and found that GLP-1 receptor agonists were associated with significantly lower progression to metastatic disease in several tumor types:
- NSCLC → ~50% lower progression risk
- Breast cancer → ~43% lower progression risk
- Colorectal cancer → ~31% lower progression risk
- Hepatocellular carcinoma → ~38% lower progression risk
Importantly:
- This was a large real-world observational study, not a randomized trial.
- GLP-1 drugs are NOT cancer treatments.
- Muscle preservation and nutritional status remain critical during cancer care.
But the signal is difficult to ignore.
The study raises an important question:
Are we entering an era where metabolic health becomes part of oncology treatment strategy—not just cancer prevention?
Study:
“GLP-1 RAs May Reduce Metastatic Progression in Certain Obesity-Related Cancers” (ASCO 2026, Abstract 3143).”
